Tourette syndrome (TS) is characterized by phonic and motor tics and psychiatric comorbidities including attention-deficit (Ϯ hyperactivity) disorder (AD/HD), obsessive-compulsive behavior (OCB), anxiety, depression, and others. 1 The efficacy and safety of deep brain stimulation (DBS) in movement disorders are established, and their applicability to neuropsychiatric conditions is expanding. We describe the results of bilateral DBS of the globus pallidus interna (GPi) in a 16-year-old boy with severe, medicationrefractory TS.
social introversion/withdrawal remained. The final monopolar stimulation parameters were achieved 6 weeks after initial programming (case ϩ, lead 2 on both sides): amplitude ϭ 5 V bilaterally, frequency ϭ 160 Hz on the right and 145 Hz on the left, pulse width ϭ 90 sec bilaterally.
Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the January 9 issue to find the link for this article.
Commentary, see page 85 Discussion. Some patients with TS experience worsening symptoms into adulthood, associated with severe physical, emotional, social, academic, and occupational difficulties. They are often refractory to medical treatments, such that surgical management is the only remaining option. This report describes a 16year-old boy treated for TS with DBS. Bilateral GPi DBS markedly improved tic frequency and severity, comorbidities, and quality of life.
The smaller changes in the VTRS are attributed to the artificial environment and brief duration of evaluation. The cognitive improvements may reflect primary beneficial DBS effects, although test-retest practice effects and improved mental clarity secondary to reduced comorbidities cannot be excluded. His poorer performance on the selective reminding memory task is of uncertain importance. The persistent social avoidance may have resulted from learned/reinforced presurgical behavior patterns.
Only 10 TS cases treated with DBS (using various sites, techniques, and evaluation methods) have been described (table E-2). We chose a GPi target because of its connections to the prefrontal cortex and because of the benefits of pallidotomy and GPi DBS in dystonia. 2 Four other TS cases successfully treated with GPi DBS support this target choice, [3] [4] [5] [6] (table E-2). Although tics were shown to uniformly improve, none of the authors detailed the pre-and postoperative test scores for the comorbidities.
Neuropsychological and psychiatric comorbidities in TS should not necessarily preclude treatment with DBS, as these conditions may improve after GPi stimulation. As surgical management of TS remains investigational, a rigid selection process, extensive experience with DBS, and comprehensive baseline and follow-up are essential for successful outcomes. 7 Larger studies comparing GPi to other targets are needed to determine the optimal target and stimulation parameters for management of disabling tics and comorbidities associated with TS. Neuroacanthocytosis (NA) encompasses a heterogeneous set of neurodegenerative disorders associated with abnormal red blood cell morphology. 1 The movement disorders of NA are often severe and incapacitating and may resist conventional drug therapy (i.e., neuroleptics and tetrabenazine). Encouraged by our previous experience in treating severe truncal spasms in a patient with chorea-acanthocytosis by chronic bilateral high-frequency stimulation of the posterior ventral oral nucleus of the thalamus 2 and by the recent literature on the treatment of chorea by bilateral internal globus pallidus stimulation, 3, 4 we proposed this technique in two cases of NA with severe and intractable movement disorders.
The first patient was a 32-year-old man with an 8-year history of choreatic-dystonic syndrome, dysarthria with recurrent distressing tasteless belching, and dramatic tongue biting. Walking was disturbed by intermittent moderate foot and back-arching dystonia. Cognitive impairment was obvious on clinical examination but impossible to test for linguistic reasons. The patient had 10% of acanthocytes among the circulating red blood cells, and an intronic mutation in the CHaC gene was consistent with the diagnosis of choreoacanthocytosis. Risperidone (up to 8 mg/day) was ineffective. The second patient exhibited chorea with hypotonia, postural instability, and a moderate cognitive deterioration. Investigations revealed 10% of acanthocytes among the circulating red blood cells. Weak expression of red blood cell Kell antigens and a mutation in the KX gene were consistent with MacLeod syndrome. Tiapride (up to 150 mg/day), risperidone (up to 5 mg/ day), and olanzapine (up to 30 mg/day) were tried unsuccessfully.
Informed consent was obtained from both patients. Under general anesthesia and electrophysiologic guidance, electrodes for chronic stimulation (deep brain stimulation [DBS]; 3387 electrode Medtronic) were positioned within the globus pallidus interna (GPi). The evaluation of electrode positions performed 3 days after electrode implantation on a cerebral CT scan combined with the preoperative three-dimensional T1-weighted MRI using a basal ganglia atlas 5 revealed that the two lowest contacts were located within the GPi (see table E-1 on the Neurology Web site at www.neurology.org). Postoperative video-based evaluation was performed 3 months after surgery by two independent movement disorder specialists (D.G. and F.T.) blinded to the postoperative conditions. Data reported in the table correspond to the mean clinical scores calculated from the clinical rating of the two blinded observers. The interrater agreement was 0.88 in Patient 1 and 0.93 in Patient 2 (perfect ϭ 1, Spearman rank test, p Ͻ 0.0001).
Clinical rating was performed on video clips of the two patients using the motor section of the Unified Huntington's Disease Rating Scale. We focus here on the results of stimulation of the two lowest contacts precisely located within the GPi. In Patient 1, chorea, belching, and dysarthria were improved by GPi 40-Hz stimulation (video Patient 1, 40-Hz mov) compared to the "off" condition (video Patient 1, Off mov). The dystonia subscore was slightly improved by 130-Hz GPi stimulation, but at this frequency, chorea and dysarthria were worsened with drooling (video Patient 1, 130-Hz mov). GPi stimulation at 10 Hz was ineffective.
See also page 92
In Patient 2, dysarthria was less pronounced, and both the dystonia and choreic symptoms were improved at 40-Hz stimulation (videos Patient 2, 40-Hz mov and Patient 2 face 40-Hz mov) compared to the "off" condition (videos Patient 2, "Off" mov and Patient 2 face "Off" mov). Conversely, GPi 130-Hz stimulation clearly worsened chorea, slightly improved facial dystonia, and induced drooling (videos Patient 2, 130-Hz mov and Patient 2 face 130-Hz mov). There was no clear improvement in hypotonia, and gait remained impossible without help, whichever stimulation parameters used. GPi stimulation at 10 Hz was ineffective.
Thus, in both patients, bilateral GPi stimulation at 40 Hz gave the best results in motor choreic disorders. Previous authors found that stimulation at various frequencies did not improve chorea in an NA patient. 6 However, they used an external pulse generator with bipolar stimulation, whereas we implanted an internal pulse generator and used monopolar stimulation on two adjacent contacts. A possible explanation could be that effective treatment of chorea requires a larger volume of stimulation. Conversely, improvement in chorea has been recently reported in a Huntington disease (HD) patient with bilateral GPi stimulation at both 130 and 40 Hz. 3 However, stimulation at 130 Hz slightly worsened bradykinesia, whereas 40 Hz had little effect. In our patients, stimulation at 130 Hz induced unacceptable side effects, worsened chorea, and induced dysarthria, pallilalia, and drooling. It is thus possible that GPi stimulation might have a different frequencydependent effect in NA and HD. In Patient 1, belching appeared to be due to the combination of a hypotonic inferior esophageal sphincter and diaphragmatic dyskinesias. GPi stimulation dramatically decreased the diaphragmatic dyskinesias, which is the most likely explanation for the improvement in belching.
The results of our pilot study need to be confirmed in a larger series of patients.
Chronic autoimmune autonomic neuropathy responsive to immunosuppressive therapy

A. Modoni; M. Mirabella; F. Madia; T. Sanna; G. Lanza; P.A. Tonali; and G. Silvestri, MD, PhD
Autoimmune autonomic neuropathy refers to a group of autoimmune disorders characterized by the failure of both sympathetic and parasympathetic systems, 1 related to the presence of autoantibodies against neuronal ganglionic acetylcholine (AChR) receptors. 2 These antibodies are detectable in the serum of about 30% of patients with paraneoplastic-acquired autoimmune autonomic neuropathy and in 50% of patients with idiopathic subacute autoimmune autonomic neuropathy. 3 We describe a 59-year-old woman who presented 6 months after the gradual development of severe dysautonomia, characterized by recurrent orthostatic syncope, dry mouth, early satiety, constipation, and urinary retention. Family history was negative and she denied any viral illness preceding the onset of the above symptoms. The results of physical examination showed her blood pressure to be 115/70 mm Hg in a supine position, but fell to 80/50 mm Hg in a sitting position; the patient was unable to stand upright for more than a few seconds because of a fainting sensation. Pupillary responses to light were torpid; however, the remaining neurologic examination was normal.
Routine blood tests, including glucose determination, were normal. X-ray gastrointestinal transit evaluation after barium ingestion documented markedly delayed gut motility without any mechanical obstruction. Urodynamic tests documented a hypotonic bladder with a post-void urinary residual requiring catheterization.
A negative Congo red staining on a periumbilical fat biopsy ruled out amyloidosis. Serum SSA, SSB antinuclear antibodies, and salivary gland biopsy were negative, excluding Sjögren disease.
Total body CT scan, colonoscopy, esophagogastroduodenoscopy, and mammography ruled out occult neoplasms.
Tilt testing, conducted at a tilt angle of 45°and interrupted after 27 minutes of passive tilt because of severe presyncopal symptoms, documented a significant drop of both systolic and diastolic blood pressure from basal values of 110/55 mm Hg to Ten milliliters of the patient's serum were collected, frozen, and sent to the Mayo Clinic Medical Laboratories (Rochester, MN) for paraneoplastic autoantibodies evaluation, including ANNA-1, -2, -3, PCA-1, -2, -Tr, anti-amphyphysin, CMRP-5, calcium channel (P/Q and N types) striated muscle, and antiganglionic AChR autoantibodies: these last resulted positive at high titers (2.12 nMol/L; normal value Ͻ0.02).
IVIg administration (0.4 mg/kg/die for 5 consecutive days) produced a marked clinical improvement commencing 5 days after the last infusion, with the patient being able to stand up and walk without experiencing any fainting sensation. Her salivary gland secretion, gut and bladder motility also recovered.
In parallel, we documented a remarkable amelioration of autonomic function tests data, thus excluding any benefit due to the increased plasma volume. Two weeks after receiving the last dose of IVIg, repeated tilt testing, conducted at a tilting angle of 45°for up to 40 minutes, did not elicit any cardiovascular symptom and was associated with physiologic modification of both blood pressure (basal 118/76 mm Hg, end-test 110/74 mm Hg) and heart rate (basal 74 bpm, end-test 82 bpm). Twenty-four-hour EKG Holter monitoring showed dramatic improvement of HRV values, both in the time-domain and in the frequency domain (figure), suggesting complete normalization of cardiac autonomic function.
The clinical improvement lasted about 4 weeks; therefore, because of relapses occurring at monthly intervals, the patient underwent repeated IVIg infusions. After the third relapse, we started treatment with a small oral prednisone dosage (25 mg/ die): this produced a further clinical improvement, lengthening the interval between relapses (3 months vs 1 month) that were also characterized by less severe clinical manifestations. In a recent report, a patient with chronic autonomic autoimmune neuropathy was successfully treated by repeated courses of plasma exchange, later on associated with immunosuppressive therapy. By monitoring systolic blood pressure, heart rate, and serum titer of antiganglionic AChR antibodies before and after plasma exchanges in the patient, the authors documented a response of chronic autoimmune autonomic neuropathy to the immunomodulatory treatment and established a causal correlation between antibody titer levels and occurrence of autonomic failure. 4 Although we did not re-evaluate in our patient the antiganglionic AChR antibodies titer levels following IVIg therapy, we could document a correlation among IVIg infusions, clinical improvement, and recovery of autonomic function test data ( figure) .
The successful use of IVIg for acute autonomic autoimmune neuropathy has been previously reported, 5,6 even though antibody testing was not performed in these studies.
This report emphasizes that, as for other autoimmune neurologic disorders, 7 IVIg therapy may be as effective as plasma exchange in chronic autonomic autoimmune neuropathy. Moreover, it also strengthens the efficacy of immunosuppressive therapy in this disorder: in fact, our patient benefited from low prednisone doses, with negligible side effects and a positive outcome on quality of life.
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